Cardiology
Latest News
COVID-19: U.S. cardiology groups reaffirm continued use of RAAS-active drugs
Experts give ACE inhibitors and ARBs, cornerstones of cardiology therapy, a thumbs up despite a hypothetical adverse COVID-19 effect.
FDA/CDC
FDA advises stopping SGLT2 inhibitor treatment prior to surgery
The changes affect canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin, and were made because surgery may put patients taking SGLT2...
Latest News
Trump to governors: Don’t wait for feds on medical supplies
President Trump outlined new guidance for Americans to avoid gatherings of more than 10 people.
Latest News
ESC says continue hypertension meds despite COVID-19 concern
European Society of Cardiology cites lack of data for theoretical link between ACE inhibitors and ARBs with COVID-19 infection risk.
Perspectives
Internist reports from COVID-19 front lines near Seattle
KENT, WASHINGTON – Dr. Elisabeth Poorman’s clinic has decided to convert all COVID-19 cases with symptoms into...
FDA/CDC
FDA to revise safety evaluation of type 2 diabetes drugs
The draft guidance will replace the requirement that manufacturers conduct cardiovascular outcomes trials to rule out unacceptable cardiovascular...
Latest News
Risk factors for death from COVID-19 identified in Wuhan patients
The odds of dying in the hospital increased with age, higher SOFA score, and D-dimer level exceeding 1 mcg/L.
Conference Coverage
Exercise needn’t be strenuous to reduce heart risk
PHOENIX – “Find the things you love to do and get moving,” Dr. Andrea Z. LaCroix advises.
News
What are the most prescribed medications for type 2 diabetes?
Empagliflozin and dulaglutide were the most-prescribed drugs in their respective classes for treating type 2 diabetes over 5 years.
News
Prescription cascade more likely after CCBs than other hypertension meds